Investor Presentaiton

Life Sciences and In Vitro Diagnostic (IVD) products to fight the COVID-19 pandemic (1/2) * eurofins Eurofins Technologies Full range of 1,500+ products/assays produced in 10 sites across 6 countries including 4 in Germany (4), and 2 in the U.S. (2): GSD NovaType III SARS-CoV-2 RT-PCR assay for the rapid detection of SARS-CoV-2 Variants of Concern including B.1.617 ("India"), B.1.427/B.1.429 ("California/USA"), B.1.351 ("South Africa") and P.1 ("Brazil"). Upgrade of COVID wastewater testing capabilities with variant detection capabilities . Novatype RT-PCR - testing for fast variant identification ○ Detect & ID RT-PCR assay, clinically validated for detecting variants such as B.1.1.7 and B.1.351, with a short turn-around time. We offer accurate and fast PCR kits to help healthcare authorities combat the COVID- 19 pandemic • GeneScan VIRSeek RT-PCR - testing kits and reagents for detection of SARS-CoV-2 in swabs of environmental surfaces о Helps employers evaluate the effectiveness of their sanitation/hygiene measures as they battle COVID-19 CE-IVD marked ELISA serology-based antibody testing kits - antibody testing for IgG, IgM and IgA, results provided in 2 hours о Assays are compatible with many open high-throughput ELISA automation platforms and can therefore provide important cost-efficient testing capacity at scale о ° Eurofins has 5 subsidiaries producing serology kits - Gold Standard Diagnostics, VIROTECH Diagnostics, NovaTec Immundiagnostica, Immunolab and Ingenesa Rapid test: lateral flow device (CE marked) - rapid test to detect total IgG, IgM and IgA antibodies at point-of-care CE-IVD marked Multiplex Real-Time RT-PCR kit - testing kit for the direct, active and qualitative pathogen detection of SARS-CoV-2, providing results in approximately 2 hours Kit demonstrates excellent performance with a 100% Negative and Positive Percent Agreement (NPA, PPA) for all tested samples and no cross-reactivity with other common widely spread coronaviruses Serology tests allow tracking the part of the population infected and may help efforts to develop vaccines and therapies 16

View entire presentation